Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Other Apr 25 | 2024Dexcom Q1 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Apr 25 | 2024Viking, AZ, Sanofi, and Merck Q1 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Apr 24 | 2024Study on Eligible Wegovy Patients through Medicare; Roche Q1 ’24 EarningsPurchase Blast
$599
Posted in: Other, SGLT2i Apr 23 | 2024Novartis Q1 ’24 Earnings; Vertex Partners with TreeFrog for T1DM ManufacturingPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Other Apr 22 | 2024SELECT up for CHMP Opinion?; April CHMP Agenda; BI Partners for MASH; Lilly Acquires Nexus Manufacturing SitePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Apr 18 | 2024Metsera Launches as Obesity Company; Lilly Initiates Ph2 Tizepatide+Mibavademab Obesity Trial; Skye Uplists to Nasdaq Global MarketPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Apr 17 | 2024SURMOUNT-OSA Topline Results; Abbott Q1 ‘24 Earnings; Lilly Insulin Settlement Dropped; NeuroBo Doses First Patient in Ph1 Obesity TrialPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other Apr 16 | 2024Nanexa’s Ph1 QM Liraglutide Study Delayed; SAB Completes Dosing in Ph1 T1DM Trial; Novartis’s Iptacopan IgAN sNDA Receives Priority Review; Ypsomed Partners with Ten23 for Patch Injector; JNJ Q1 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Apr 12 | 2024Lilly Loses Counterfeit Tirzepatide Lawsuit; EMA Finds No Link Between GLP-1RAs and Suicide Ideation; Diamyd Ph3 Recruitment UpdatePurchase Blast
$599
Posted in: GLP-1RA, Other Apr 11 | 2024Lipocine Ph2 Obesity Results; 89bio Enters Manufacturing PartnershipPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Apr 10 | 2024Novo Expands Ginkgo Partnership; Dexcom Integrates New Remote Care Platform; LIB Presents Ph3 PCSK9i Data at ACC 2024Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Apr 09 | 2024Lilly Initiates Third Ph3 Retatrutide T2DM Trial; Rezdiffra Now Available in the US; Galectin to Continue Belapectin MASH Development; Arrowhead Presents at ACC 2024; BI Initiates New Obesity TrialsPurchase Blast
$599
Posted in: GLP-1RA, Other, SGLT2i Apr 08 | 2024ACC 2024: Novo, Roche/Alnylam, Esperion, Novartis, and Amarin Present New Data; Novo Resubmits Catalent Acquisition Application; AZ Initiates Ph2 Balcinrenone/Dapa Trial in CKD; Silence Publishes Ph1 Lp(a) Results; Teladoc CEO Steps DownPurchase Blast
$599
Posted in: Glucose Monitoring, Other Apr 04 | 2024Ascletis MASH Development Updates; Biolinq Raises $58M for Intradermal Glucose Sensor; Arrowhead Initiates Ph3 Plozasiran TrialsPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, SGLT2i Apr 03 | 2024Clive Meanwell and Ian Reed Take on the Obesity Market; Novo Initiates Icodec Switching Trial; Mounjaro Faces Continued US Supply Constraints; Amarin’s Vazkepa Exclusivity ExtendedPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Apr 02 | 2024Biomea and Fractyl Q4 ’23 Earnings; Glucotrack Implantable CGM Update; Costco Weight Loss Program; D&D Fast Track Designation in MASH; New Aligos Ph2a MASH Trial; Sernova Cell Pouch UpdatesPurchase Blast
$599
Posted in: GLP-1RA, Other Apr 01 | 2024Zepbound Supply Constraints Observed; NeuroBo Completes Ph2a MASH Trial Enrollment; Galectin Q4 ’23 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Mar 28 | 2024FDA Approves Akebia’s Vadadustat; Inventiva and NeuroBo Q4 ’23 Earnings; Supersapiens to Relaunch in US; Sagimet MASH Development UpdatesPurchase Blast